BioCentury
ARTICLE | Product Development

AML advances

ASH 2016: How AML could see a slew of new targeted therapies in the coming years

December 10, 2016 4:24 AM UTC

Treatment paradigms in most cancers have followed a predictable if sometimes slow progression from chemotherapy, to agents that target features prevalent among a classically defined cancer type, to personalized approaches targeting features specific to an individual patient’s cancer. Data on AML presented at the American Society of Hematology meeting show that, after decades stuck at step one, the rare leukemia could soon jump straight to step three.

A couple weeks before ASH, Novartis AG announced that FDA had granted Priority Review to midostaurin to treat newly diagnosed acute myelogenous leukemia that is positive for FMS-like tyrosine kinase 3 (FLT3; CD135). The PDUFA date is not disclosed but would be expected in mid-May given a six-month review...